Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness. [electronic resource]
Producer: 20151109Description: 190-4 p. digitalISSN:- 1369-1635
- Antibodies, Monoclonal, Murine-Derived -- therapeutic use
- Antigens, Human Platelet -- immunology
- Blood Platelet Disorders -- blood
- Female
- HLA Antigens -- immunology
- Humans
- Immunoglobulins, Intravenous
- Immunologic Factors -- therapeutic use
- Middle Aged
- Plasma Exchange
- Platelet Count
- Platelet Transfusion -- adverse effects
- Rituximab
- Treatment Outcome
No physical items for this record
Publication Type: Case Reports; Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.